Results 131 to 140 of about 4,942 (259)

Estimating the effect of inclisiran on hypercholesterolemia and primary prevention of cardiovascular disease: the NHANES 1999–2018 study

Lipids in Health and Disease
Background Hypercholesterolemia has been identified as an independent predictor of cardiovascular disease (CVD). Inclisiran, an innovative small interfering RNA agent, is anticipated to result in a notable reduction of approximately 50% in low-density ...
Haonan Li, Song Zhao, Jiawen Wu, Jun Han, Yawei Xu, Shengfeng Shi, Yi Zhang   +6 more
doaj   +1 more source

Inclisiran in patients with acute ischemic stroke: first data

, 2023
M. S. Cherepyansky, G. M. Ponomareva, I. B. Skiba, R. M. Abakarov, V. V. Dudayte, A. A. Cherepianskaia   +5 more
openalex   +2 more sources

Efficacy and safety of inclisiran, evolocumab and alirocumab in patients with high, very high and extreme cardiovascular risk

Russian Journal of Cardiology
Aim. To compare efficacy and safety of inclisiran, evolocumab and alirocumab in patients with high, very high and extreme cardiovascular risk (according to data from the Federal Research Center for Cardiology and Microbiology, Novosibirsk).Material and ...
N. G. Lozhkina, N. P. Dobrovolskaya, S. N. Artemenko, M. V. Shipunov, A. D. Sharonin, V. A. Koltyugina, V. Timofeev, M. Voyevoda   +7 more
semanticscholar   +1 more source

First Russian experience of treating dyslipidemia with siRNA drugs in patients after heart transplantation

Российский кардиологический журнал
Patients after heart transplantation (HT) are at very high risk for cardiovascular disease. Protocols for the management of heart recipients include the initiation of lipid-lowering therapy (LLT), regardless of sex, age and origin of heart failure. Given
M. A. Simonenko, A. S. Alieva, M. Yu. Sitnikova, P. A. Fedotov   +3 more
doaj   +1 more source

CSI NIC Mid Term Meet: NIC 2024 [PDF]

CONFERENCE ...
IJCP
core   +2 more sources

Hypolypidemic therapy in the XXI century: what is new?

RUDN Journal of Medicine
Relevance. The leading position in mortality throughout the world is occupied by cardiovascular diseases, caused be atherosclerosis process. Statins used to be the gold standard of lipid-lowering therapy for a long time due to their high efficacy ...
Natalya Yu. Ob’edkova, Diana N. Usacheva, Galina S. Mal, Evgenij G. Ob’edkov   +3 more
doaj   +1 more source

PCSK9 antagonists and inflammation [PDF]

, 2018
Corsini, Alberto, Ferri, Nicola, Ruscica, Massimiliano, Sirtori, Cesare R.   +3 more
core   +1 more source

New drugs for the treatment of hyperlipidemia in statin-intolerant patients - review [PDF]

Introduction Cardiovascular diseases are the most numerous group of diseases prevalent in the world. They are a challenge for many health systems, in terms of keeping life comfortable and also economics. The cause of selected disease entities is too much
Banach, Krzysztof, Bułatowicz, Monika, Chruścicki, Damian, Liber, Joanna, Pelc, Marcin, Pławiak, Aleksandra, Płonka, Wojtek, Sitarek, Gracjan, Żerek, Marta   +8 more
core   +1 more source

NANOSPRESSO: toward personalized, locally produced nucleic acid nanomedicines [PDF]

The NANOSPRESSO project is a pioneering response to the complex challenge of treating orphan diseases, which, despite affecting millions of people globally, have only scant therapeutic options.
Barriga, Hanna MG, Borgos, Sven Even, Campbell, Fred, Ceccaldi, Alexandre, Cullis, Pieter, de Beer, Joel, De Bruin, Marie L., Dekker, Jan, Dorst-Mooiman, Kim D., Estapé Senti, Mariona, Fuchs, Sabine, Geerlings, Maurits W., Hannus, Michael, Holig, Peter, IJzerman, Maarten, Luciani, Marta, Saber, Nadine, Schurmann, Paul J. L., Segers, Tim, Stevens, Molly M., van Hoeve, Wim, Westerik, Maurits, Winter, Martin, Wolbers, Floor   +23 more
core   +2 more sources

Efficacy and Safety of Inclisiran in Asian Patients

, 2023
Yong Huo, Anastasia Lesogor, Cheol Whan Lee, Chern‐En Chiang, Jorge Mena-Madrazo, Kian Keong Poh, Myung Ho Jeong, Pierre Maheux, Mengli Zhang, Suning Wei, Yajun Han, Yong Li   +11 more
openalex   +1 more source